La cadena de opciones muestra datos clave de las opciones de acciones de IO Biotech a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para IO Biotech..

IO Biotech (NASDAQ:IOBT) Bolsa, Cadena de Opciones

IO BIOTECH INC

IO Biotech

IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.

Five,Below,Now,Open,-,Closeup,Of,Sign,On,Building

AGMH

AKBA

BHIL

DEVS

EFXT

FIVE

IOBT

MAZE

MHUA

OPTN

RVSB

VRPX

ZCAR

Las acciones de Five Below se disparan tras superar expectativas. Conoce otros grandes movimientos bursátiles en el premercado de EE.UU.

Las acciones de Five Below (FIVE) suben un 12%; Aquí están 20 acciones que se mueven en premercado

IO Biotech Inc

Press Releases

IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170

News

Health Care

General

IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025

Earnings

IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights

IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference

IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed

Small Cap

Opinion

Biotech Stocks Rally as Oncology Market Targets $866B by 2034

IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Biotech at a Pivotal Moment: Four Stocks Defining The Transformation (MDCX, IOBT, INSM, RNA)

INSM

MDCX

OLMA

ONCY

PDSB

PRPH

TSX:ONC

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Anika Therapeutics

Avalo Therapeutics

Biomea Fusion

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

Coya Therapeutics

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

Citius Oncology

Fate Therapeutics

Genelux

HilleVax

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals

Molecular Partners AG - American Depositary Shares

Molecular Partners

Oncolytics Biotech

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

AVITA Medical

Skye Bioscience

Spero Therapeutics

Surrozen

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

TScan Therapeutics

XBiotech

Zura Bio Limited - Class A Ordinary shares

Zura Bio

Morgan Stanley

HC Wainwright & Co.

Piper Sandler

Comments

IO Biotech

IO Biotech (IOBT) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL